Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Coherus Oncology, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 188
- −17 vs. Q1 2021
- Shares held
- 77.9M
- −2.44M (−3.0%) vs. Q1 2021
- Total value
- $1.08B
- −$96.9M (−8.3%) vs. Q1 2021
- New holders
- 21
- 81 more added
- Sold out
- 38
- 58 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CHRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 146 | $98.5M |
| Q1 2026 | 158 | $120.8M |
| Q4 2025 | 128 | $81.1M |
| Q3 2025 | 114 | $84.6M |
| Q2 2025 | 112 | $40.4M |
| Q1 2025 | 117 | $50.0M |
| Q4 2024 | 124 | $90.5M |
| Q3 2024 | 128 | $79.9M |
| Q2 2024 | 135 | $142.9M |
| Q1 2024 | 137 | $197.6M |
| Q4 2023 | 156 | $271.4M |
| Q3 2023 | 169 | $347.6M |
| Q2 2023 | 161 | $371.1M |
| Q1 2023 | 163 | $536.5M |
| Q4 2022 | 161 | $622.7M |
| Q3 2022 | 174 | $743.4M |
| Q2 2022 | 176 | $572.0M |
| Q1 2022 | 184 | $980.7M |
| Q4 2021 | 201 | $1.23B |
| Q3 2021 | 188 | $1.22B |
| Q2 2021 | 188 | $1.08B |
| Q1 2021 | 205 | $1.17B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Coherus Oncology, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −98,160−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −66,535−100.0% | Sold out |
| Prairiewood Capital, LLC | 0 | $0 | 0.00% | −52,292−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −50,716−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −49,059−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −46,735−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −39,924−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −34,610−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −32,947−100.0% | Sold out |
| Blueshift Asset Management, LLC | 0 | $0 | 0.00% | −31,995−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −26,928−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −24,133−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −19,103−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −18,601−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −15,893−100.0% | Sold out |
| LS Investment Advisors, LLC | 0 | $0 | 0.00% | −15,154−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −13,273−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −7,479−100.0% | Sold out |
| First Command Bank | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| First Command Financial Services, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −161−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −76−100.0% | Sold out |
| Harvest Group Wealth Management, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Fieldpoint Private Securities, LLC | 0 | $0 | 0.00% | −65−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −5−100.0% | Sold out |